Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal associations of cardiovascular health and vascular events with incident dementia.

Stroke and vascular neurology·2023
Same author

Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy.

Journal of Parkinson's disease·2023
Same author

Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.

Molecular neurobiology·2023
Same author

Association of biological age with health outcomes and its modifiable factors.

Aging cell·2023
Same author

The causal role of circulating amino acids on neurodegenerative disorders: A two-sample Mendelian randomization study.

Journal of neurochemistry·2023
Same author

TMEM106B aggregation in neurodegenerative diseases: linking genetics to function.

Molecular neurodegeneration·2023
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Jin-Tai Yu1,2, Jun Wang3, Yu-Yuan Huang4

  • 1National Center for Neurological Disorders, Shanghai, China.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

The novel [18F]Florzolotau PET tracer accurately detects tau pathology in cognitive disorders. This tau PET imaging significantly improved diagnosis, confidence, and treatment plans in patients with cognitive symptoms.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • The novel positron emission tomography (PET) tracer [18F]Florzolotau enables in vivo detection of tau pathology.
  • [18F]Florzolotau exhibits a disease-specific spatial pattern for tau distribution.
  • The study aimed to assess the diagnostic accuracy and added value of [18F]Florzolotau PET in patients with cognitive symptoms.

Purpose of the Study:

  • Evaluate the diagnostic accuracy of [18F]Florzolotau PET for identifying tauopathies.
  • Determine the added value of [18F]Florzolotau PET to standard clinical workup.
  • Assess changes in diagnosis, diagnostic confidence, and treatment plans post-PET imaging.

Main Methods:

  • A real-world cohort study included 1476 participants with cognitive complaints.
  • Standard diagnostic workup plus [18F]Florzolotau tau PET scans were performed.
  • Clinicians reported diagnoses and confidence before and after PET interpretation.

Main Results:

  • [18F]Florzolotau PET showed high accuracy in differentiating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and corticobasal syndrome.
  • PET imaging led to diagnostic changes in 21.5% of participants and increased diagnostic confidence from 67.7% to 80.7%.
  • Medication plans were altered in 27.4% of participants based on PET findings.

Conclusions:

  • [18F]Florzolotau tau PET demonstrates high accuracy in classifying cognitive disorders.
  • The tracer provides significant added value to routine clinical evaluations for cognitive symptoms.
  • Its utility is particularly notable in patients with mild cognitive impairment or dementia and lower initial diagnostic confidence.